O&G Forum

• GONAPEPTYL ® DAILY is indicated for down-regulation and prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) 1 • The GnRH agonist GONAPEPTYL ® DAILY is an analogue of natural hypothalamic GnRH 2,3 • GONAPEPTYL ® DAILY is provided in a convenient pre-filled syringe avoiding the need for patients to daily reconstitute a powder with solvent 1 triptorelin acetate 100 µg/1ml 100 NEW References: 1. GONAPEPTYL DAILY Registered Package Insert, dated 11 August 2020. 2. Ortmann O, et al. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online 2002;5 Suppl 1(3):1–7. 3. Millar RP, et al. Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:235–275 NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION: Ferring (Pty.) Ltd. Route 21 Corporate Park, 6 Regency Drive, Irene Ext 30, Pretoria, South Africa. Tel: +27 12 345 6358. Fax: +27 12 345 1156. www.ferring.co.za. GONAPEPTYL, FERRING, and the FERRING logo are registered trademarks of Ferring B.V. For full prescribing information please refer to the package insert approved by the medicines regulatory authority. https://bit.ly/3hUP4km. 2021/019 Date of preparation: April 2021. S4 GONAPEPTYLDAILY. Each syringe with 1 ml solution contains 100 μg triptorelin acetate equivalent to 95,6 micrograms triptorelin free base. Reg. No. 46/21.10/0169.